Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2025
Reporting Period: Fiscal First Quarter ended March 31, 2025
This filing serves as a notification that the Company announced its financial results for the first quarter of fiscal 2025 via a press release dated May 8, 2025. The press release is incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The filing explicitly states that the detailed results are contained in the attached press release (Exhibit 99.1), which is not included in the input text.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the referenced press release for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of Q1 2025 results but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain actual revenue, net income, and cash flow figures for the quarter ended March 31, 2025.
- Verify if the press release contains updated financial guidance or forward-looking statements not present in this 8-K summary.
- Confirm the trading symbol (ORGO) and exchange (Nasdaq Capital Market) for accurate market data retrieval.